Clinical Trial News and Research

RSS

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd. today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.

23 Jun 2014

Celsion acquires all assets of EGEN

Celsion Corporation, an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of the assets of EGEN, Inc., a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases.

21 Jun 2014

Arthritis drug promotes hair growth in hairless man

A man with almost no hair on his body has grown a full head of it after a novel treatment by doctors at Yale University.

20 Jun 2014

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

20 Jun 2014

New treatment for ovarian cancer can improve response rates

Doctors at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center in Phoenix reported today in Lancet Oncology that a new treatment for ovarian cancer can improve response rates (increase the rate of tumor shrinkage) and prolong the time until cancers recur.

20 Jun 2014

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.

18 Jun 2014

Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Animas Corporation today shared encouraging results from its predictive hypoglycemia-minimizing algorithm in development.

18 Jun 2014

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

18 Jun 2014

Single dose restores normal cellular signaling in mouse model of autism

In a further test of a novel theory that suggests autism is the consequence of abnormal cell communication, researchers at the University of California, San Diego School of Medicine report that an almost century-old drug approved for treating sleeping sickness also restores normal cellular signaling in a mouse model of autism, reversing symptoms of the neurological disorder in animals that were the human biological age equivalent of 30 years old.

18 Jun 2014

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA).

17 Jun 2014

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

Research One, Inc., an affiliate of Orlando Heart Specialists (OHS), is seeking candidates for a clinical drug trial that could reduce cholesterol levels with just one injection, twice a month.

17 Jun 2014

Lowering systolic blood pressure below 120 does not appear to provide additional benefit

For decades, common medical wisdom has been "the lower the better" in treating the approximately one in three people in this country who have high blood pressure.

17 Jun 2014

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials.

From Clario 16 Jun 2014

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Medical investigators at the Virginia G. Piper Cancer Center at Scottsdale Healthcare are studying a new cancer immunotherapy to see if it can successfully help patients with advanced pancreatic cancer.

16 Jun 2014

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region.

16 Jun 2014

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months.

13 Jun 2014

2 medications equally effective in treating major epileptic brain seizures in children

A recently published clinical study in the Journal of the American Medical Association has answered an urgent question that long puzzled ER pediatricians: Is the drug lorazepam really safer and more effective than diazepam - the U.S. Food and Drug Administration-approved medication as first line therapy most often used by emergency room doctors to control major epileptic seizures in children?

13 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Cogstate announces signing of first contract for Precision Recruitment tool

Cognition technology company Cogstate is pleased to announce the signing of its first contract for Precision Recruitment, a new web-based tool for streamlining patient recruitment for clinical drug trials.

12 Jun 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

Clinical Trial News and Research

Chinese FDA accepts Lee's IND for Phase 2 dry eye study

Celsion acquires all assets of EGEN

Arthritis drug promotes hair growth in hairless man

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

New treatment for ovarian cancer can improve response rates

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Animas' predictive algorithm technology maintains glucose above hypoglycemic levels

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

Single dose restores normal cellular signaling in mouse model of autism

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

Lowering systolic blood pressure below 120 does not appear to provide additional benefit

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

2 medications equally effective in treating major epileptic brain seizures in children

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Cogstate announces signing of first contract for Precision Recruitment tool

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer